These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19541584)

  • 1. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease.
    Kastenbauer U; Wolf E; Kollan C; Hamouda O; Bogner JR;
    Eur J Med Res; 2009 Jun; 14(6):244-9. PubMed ID: 19541584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection.
    Mansharamani NG; Balachandran D; Vernovsky I; Garland R; Koziel H
    Chest; 2000 Sep; 118(3):712-20. PubMed ID: 10988193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
    Costiniuk CT; Fergusson DA; Doucette S; Angel JB
    PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection.
    Enomoto T; Azuma A; Kohno A; Kaneko K; Saito H; Kametaka M; Usuki J; Gemma A; Kudoh S; Nakamura S
    Respirology; 2010 Jan; 15(1):126-31. PubMed ID: 19947989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pneumocystis jiroveci pneumonia characteristics in adults with AIDS with or without antiretroviral therapy].
    Bahamondes M L; Villar Z MJ; Orellana C C; González R J; Montenegro U C
    Rev Chilena Infectol; 2006 Sep; 23(3):215-9. PubMed ID: 16896493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxoplasma encephalitis in an HIV-infected patient on highly active antiretroviral therapy despite sustained immune response.
    Atreya AR; Arora S; Gadiraju VT; Martagon-Villamil J; Skiest DJ
    Int J STD AIDS; 2014 Apr; 25(5):383-6. PubMed ID: 24108450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
    Bossi P; Caumes E; Astagneau P; Li TS; Paris L; Mengual X; Katlama C; Bricaire F
    Rev Med Interne; 1998 May; 19(5):313-7. PubMed ID: 9775164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
    Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
    Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
    AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine.
    Köppen S; Grünewald T; Jautzke G; Gottschalk J; Pohle HD; Ruf B
    Clin Investig; 1992 Jun; 70(6):508-12. PubMed ID: 1356529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
    Schäfer G; Hoffmann C; Arasteh K; Schürmann D; Stephan C; Jensen B; Stoll M; Bogner JR; Faetkenheuer G; Rockstroh J; Klinker H; Härter G; Stöhr A; Degen O; Freiwald E; Hüfner A; Jordan S; Schulze Zur Wiesch J; Addo M; Lohse AW; van Lunzen J; Schmiedel S;
    AIDS Res Ther; 2019 Nov; 16(1):34. PubMed ID: 31729999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial.
    Qin Y; Lu Y; Zhou Y; Harypursat V; Sun F; Yang S; Tang S; Li Y; He X; Zeng Y; Chen Y
    Trials; 2020 Jun; 21(1):551. PubMed ID: 32571429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
    AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune reconstitution inflammatory syndrome associated with toxoplasmic encephalitis in HIV-infected patients.
    van Bilsen WPH; van den Berg CHSB; Rijnders BJA; Brinkman K; Mulder JW; Gelinck LBS; Hoepelman AIM; Wit FWNM; van de Beek D; Prins JM
    AIDS; 2017 Jun; 31(10):1415-1424. PubMed ID: 28375874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.